Through analysis of 1015 primary and 358 metastatic melanomas, Taylor E Aronff et al. [23] found that amplifications of MDM4 are associated with higher rate of metastasis, poorer therapeutic efficacy of immunotherapy and lower overall survival in metastatic melanomas. Here, MDM4 is linked to metastatic melanoma.